Inovio Pharmaceuticals, Inc.

INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024.

Revenue
−83.2%
EPS
+88.5%
Free cash flow
+13.4%

Quarter to June 2026, against a year earlier

1.22 0.23 −15.86%
Market cap
$125.6M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
1/9
ROIC
0.00%
Net debt / EBITDA
0.7×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.00 1.04 1.40 0.79
Net Debt/EBITDA
2.05 1.78 3.49 2.49
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.22) (0.31) (0.42) (0.41)
Book value per Share
0.05 0.09 0.51 (0.15)
Free Cash Flow
(18.05) (21.59) (19.50) (21.64)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026